gutflix
GI learning, personalised

Summary

LONG NON-CODING NPTN-IT1 AS A NEW THERAPEUTIC MODALITY FOR HEPATOCELLULAR CARCINOMA

Mona Zoheiry

UEG Week Copenhagen 2023 | Poster

Hepatobiliary

October 15, 2023

A mouse study tested intrahepatic lncRNA NPTN-IT1 administration as a potential therapeutic modality for hepatocellular carcinoma induced by N-Nitrosodiethylamine.

KEY POINTS

- In a three-group mouse experiment (n=60), Group 2 received DEN weekly for 16 weeks to induce HCC, while Group 3 additionally received intrahepatic lncRNA NPTN-IT1 once weekly for four weeks starting at week 12.
- NPTN-IT1 administration resulted in HCC regression with restoration of normal liver architecture as assessed by pathological examination.
- Treatment significantly decreased AFP, VEGF, and TNF-α levels ($P<0.001$) and significantly down-regulated relative expression of cyclin-D1 and TGF-b1 ($P<0.001$).
- The authors propose that lncRNA NPTN-IT1 can be considered a new therapeutic modality for hepatocellular carcinoma based on these preclinical findings.
- This work is relevant to researchers investigating novel molecular therapeutic approaches for hepatocellular carcinoma.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/9255829a-743c-11ee-8362-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.